RxDoctor Payments DataLook up a doctor →

Kevin Wietecha, DO

Endocrinology, Diabetes & Metabolism · Canton, OHNPI 1669450557

Payments from drug & device makers

$127,337in general payments, 2019–2025

Across 354 payments — averaging $359.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$85K
  • AstraZeneca$25K
  • Bayer$12K
  • Tandem Diabetes Care, Inc.$3K
  • Lilly USA, LLC$329
  • Amgen$276
  • plus $2K from 36 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk131$85,041
AstraZeneca(2 entities)41$25,124
Bayer21$11,649
Tandem Diabetes Care, Inc.15$3,001
Lilly USA, LLC19$329
Amgen(2 entities)15$276
Novartis9$157
Dexcom, Inc.7$151
Sanofi-aventis U.S. LLC8$140
Corcept Therapeutics5$118
Insulet Corporation7$113
Amarin Pharma, Inc.7$103
Antares Pharma, Inc.6$101
Medtronic(2 entities)5$85
Boehringer Ingelheim6$85
Xeris Pharmaceuticals, Inc.5$83
Abbott5$80
Pfizer5$71
AbbVie3$56
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$52
Radius Health, Inc.3$50
BETA Bionics, Inc.2$46
IBSA Pharma Inc.3$39
Amryt Pharma Holdings Ltd2$32
Esperion Therapeutics, Inc.2$29
Merck2$28
Ultragenyx Pharmaceutical Inc.1$28
Ascensia Diabetes Care US Inc.2$27
OPKO Pharmaceuticals, LLC1$24
Averitas Pharma Inc.1$23
Sun Pharmaceutical Industries Inc.1$21
Eisai Inc.1$20
Roche Diabetes Care, Inc.1$19
GE HealthCare1$18
Recordati_rare_diseases_inc.1$18
Regeneron Healthcare Solutions, Inc.1$17
Mannkind Corporation1$17
Ascendis Pharma Endocrinology Inc1$15
Amneal Pharmaceuticals LLC1$15
Ipsen Biopharmaceuticals, Inc1$13
Cequr Corporation1$12
Johnson & Johnson1$11

How this compares

$127,337 in reported general payments places this provider in the 85th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio →

Medicare billing

Part B allowed, 2024
$429,073
Medicare patients
1,083
Services billed
5,751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Canton

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →